The first gene therapy for sickle cell anemia has been approved in the UK

In November we received the news that the world's first gene therapy has been approved by the UK regulators. The therapy named Casgevy has been developed by Vertex and is based on the genetic engeneering method called CRISPR. This method is used in our research consortium as well, so the news of UK approval has been a major step for us too. Nevertheless, the approval comes with the same social questions applicable to our research. Since the therapy is incredibly costly, for whom will it become available? Read more about it in this article written by Nature.